Lipase

Global Baking Enzymes Market (2021 to 2028) - Share, Size, Trends & Industry Analysis Report - ResearchAndMarkets.com

Retrieved on: 
Friday, April 23, 2021
Food, Beverage, Retail, Baking industry, Baking, Food science, Lipase

b'The "Baking Enzymes Market Share, Size, Trends, Industry Analysis Report, By Type; By Application; By Region; Segment Forecast, 2021 - 2028" report has been added to ResearchAndMarkets.com\'s offering.\nThe global baking enzymes market size is expected to reach $1,115.6 million by 2028 according to a new study.

Key Points: 
  • b'The "Baking Enzymes Market Share, Size, Trends, Industry Analysis Report, By Type; By Application; By Region; Segment Forecast, 2021 - 2028" report has been added to ResearchAndMarkets.com\'s offering.\nThe global baking enzymes market size is expected to reach $1,115.6 million by 2028 according to a new study.
  • The busy lifestyle of consumers is leading to an increase in consumption of convenience and on-the-go meals, supporting the growth of the market for baking enzymes.
  • Furthermore, increasing health awareness and technological advancements in food science are factors expected to provide numerous growth opportunities to the global baking enzymes industry over the coming years.\nThe different types of baking enzymes include protease, carbohydrase, lipase, and others.
  • The carbohydrase segment accounted for a significant market share in the global baking enzymes industry in 2020 owing to its high thermal stability, which aids its use in several baking applications.

Familial Lipoprotein Lipase Deficiency: A Rare Inherited Condition, in Which the Normal Breakdown of Fats in the Body is Affected - Global Pipeline Insight Report 2020 - ResearchAndMarkets.com

Retrieved on: 
Friday, April 2, 2021
Health, General Health, Branches of biology, Metabolic disorders, Lipids, Lipid metabolism disorders, Lipoprotein lipase deficiency, Cardiology, Lipase, Lipoprotein lipase, Lipoprotein, Triglyceride, Hyperlipidemia, Acid lipase disease

The "Familial Lipoprotein Lipase Deficiency - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Familial Lipoprotein Lipase Deficiency - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "Familial Lipoprotein Lipase Deficiency - Pipeline Insight, 2020," report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Familial Lipoprotein Lipase Deficiency pipeline landscape.
  • Familial Lipoprotein Lipase Deficiency (LPLD) is a rare inherited condition, in which the normal breakdown of fats in the body is affected.
  • Treatment for Familial Lipoprotein Lipase Deficiency aims to control the symptoms and blood triglyceride levels with a very low-fat diet.

AzurRx BioPharma Announces Completion of Enrollment in Phase 2 Clinical Trial of MS1819 in Combination with PERT in the Treatment of Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency

Retrieved on: 
Monday, March 22, 2021
Pancreas disorders, Medical specialties, Clinical medicine, Gastroenterology, Chronic pancreatitis, Exocrine pancreatic insufficiency, Pancreatitis, Cystic fibrosis, Lipase, Insufficiency, Anthera Pharmaceuticals, Pancreatic disease

We are very pleased to have completed enrollment in our Phase 2 MS1819 plus PERT combination therapy clinical trial, said James Sapirstein, President, CEO and Chairman of AzurRx.

Key Points: 
  • We are very pleased to have completed enrollment in our Phase 2 MS1819 plus PERT combination therapy clinical trial, said James Sapirstein, President, CEO and Chairman of AzurRx.
  • We continue to remain on target to report topline results from the combination therapy study during the second quarter of 2021.
  • MS1819 is a recombinant lipase enzyme for the treatment of exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis.
  • The lead therapeutic candidate isMS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis,currently in two Phase 2 clinical trials.

AzurRx BioPharma to Participate in “Fireside Chat” at the H.C. Wainwright Global Life Sciences Conference

Retrieved on: 
Tuesday, March 2, 2021
Pancreas disorders, Medical specialties, Gastroenterology, Organ systems, Exocrine pancreatic insufficiency, Chronic pancreatitis, Pancreatitis, Cystic fibrosis, Pancreas, Lipase, Insufficiency, Gastrointestinal disease

AzurRx BioPharma, Inc. (NASDAQ: AZRX) is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases.

Key Points: 
  • AzurRx BioPharma, Inc. (NASDAQ: AZRX) is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases.
  • The Company has a pipeline of three gut-restricted GI clinical programs.
  • The lead therapeutic candidate isMS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis, currently in two Phase 2 clinical trials.
  • This press release may contain certain statements relating to future results which are forward-looking statements.

Global Dairy Enzymes (Carbohydrases, Proteases, Polymerases & Nucleases, Lipases, Phytases) Market Share, Size, Trends, Industry Analysis Report 2020-2027 - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 25, 2021
Food, Beverage, Retail, Food and drink, Dairy products, Non-alcoholic drinks, Catalysis, Milk, Lactose, Lactase, Dairy, Enzyme, Cheese, Lipase, Lactase persistence

The "Dairy Enzymes Market Share, Size, Trends, Industry Analysis Report, By Product Class; By Source; By Application; By Regions - Segment Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Dairy Enzymes Market Share, Size, Trends, Industry Analysis Report, By Product Class; By Source; By Application; By Regions - Segment Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering.
  • Dairy enzymes refer to the enzymes that are added to milk for production of various dairy products such as cheese, yoghurt and other milk products.
  • Various dairy enzymes such as lipases, proteases, catalase, and lactase have a variety of dairy applications.
  • For instance, in May 2020, DuPont Nutrition & Biosciences introduced its novel bonlacta enzyme for the North American lactose-free dairy market.

AzurRx BioPharma Adds Two New Clinical Trial Sites in Europe for Phase 2b OPTION 2 Extension Study of MS1819 Immediate-Release Capsules in Cystic Fibrosis Patients

Retrieved on: 
Tuesday, January 26, 2021
Pancreas disorders, Medical specialties, Clinical medicine, Organ systems, Chronic pancreatitis, Exocrine pancreatic insufficiency, Pancreatitis, Cystic fibrosis, Pancreas, Lipase, Insufficiency, Pancreatic enzymes

Additional sites were added in Europe to minimize any potential patient enrollment delays during the ongoing COVID-19 pandemic.

Key Points: 
  • Additional sites were added in Europe to minimize any potential patient enrollment delays during the ongoing COVID-19 pandemic.
  • The extension arm of the Phase 2b OPTION 2 trial is designed to test immediate release capsules to identify the optimal dose and delivery method of MS1819.
  • The extension arm will enroll patients 18 years or older who have completed the OPTION 2 crossover trial at higher dose levels relative to the previous OPTION 1 trial.
  • MS1819 is a recombinant lipase enzyme for the treatment of exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis.

AzurRx BioPharma Announces First Two Patients Dosed in Phase 2b OPTION 2 Extension Study of MS1819 in Cystic Fibrosis Patients

Retrieved on: 
Thursday, January 21, 2021
Pancreas disorders, Medical specialties, Clinical medicine, Organ systems, Chronic pancreatitis, Pancreatitis, Exocrine pancreatic insufficiency, Cystic fibrosis, Lipase, Pancreas, Pancreatic enzymes, Pancreatic disease

The company recently announced an additional study arm in the Phase 2b OPTION 2 study utilizing immediate release capsules in efforts to identify the optimal dose and delivery method of MS1819.

Key Points: 
  • The company recently announced an additional study arm in the Phase 2b OPTION 2 study utilizing immediate release capsules in efforts to identify the optimal dose and delivery method of MS1819.
  • The OPTION 2 extension phase design will test patients 18 years or older, who have already completed the OPTION 2 crossover trial, at higher doses relative to the previously conducted OPTION 1 trial.
  • As of today, two patients have been dosed and will continue to be treated for the duration of the next two weeks.
  • MS1819 is a recombinant lipase enzyme for the treatment of exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis.

AzurRx BioPharma Announces First Patients Dosed in Turkey for Phase 2 Combination Therapy Trial of MS1819 in Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency

Retrieved on: 
Monday, November 30, 2020
Pancreas disorders, Medical specialties, Clinical medicine, Organ systems, Chronic pancreatitis, Pancreatic enzymes, Cystic fibrosis, Exocrine pancreatic insufficiency, Pancreatitis, Lipase, Anthera Pharmaceuticals, Pancreatic elastase

Earlier last month, the Company reported that additional clinical sites were activated in Turkey, which follows Hungary as the second country where patients have been screened and dosed in the Combination trial.

Key Points: 
  • Earlier last month, the Company reported that additional clinical sites were activated in Turkey, which follows Hungary as the second country where patients have been screened and dosed in the Combination trial.
  • As of today, there are five sites activated in Turkey that are currently screening for patients.
  • MS1819 is a recombinant lipase enzyme for the treatment of exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis.
  • AzurRx is currently conducting two Phase 2clinical trialsof MS1819: the OPTION 2 monotherapy trial, and the Combination therapy trial,consistingof MS1819 in conjunction with porcine-derivedpancreatic enzyme replacement therapy, the current standard of care.

AzurRx BioPharma Activates Additional Clinical Trial Sites in Turkey for Phase 2 Combination Therapy Trial of MS1819 in Cystic Fibrosis

Retrieved on: 
Wednesday, October 14, 2020
Pancreas disorders, Medical specialties, Digestive diseases, Clinical medicine, RTT, Chronic pancreatitis, Exocrine pancreatic insufficiency, Pancreatic enzymes, Pancreatitis, Cystic fibrosis, Lipase, Pancreas

A total of eight of the expected twelve sites in Europe are now active and recruiting patients.

Key Points: 
  • A total of eight of the expected twelve sites in Europe are now active and recruiting patients.
  • We are truly pleased and encouraged by the interest in our expanding global Phase 2 Combination Trial, said Dr. James Pennington, Chief Medical Officer of AzurRx.
  • The digestive standard of care for both CF and chronic pancreatitis (CP) patients with EPI are commercially-available porcine pancreatic enzyme replacement therapy (PERTs).
  • MS1819 is a recombinant lipase enzyme for the treatment of exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis.

AzurRx BioPharma Initiates European Arm of Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis

Retrieved on: 
Monday, August 17, 2020
Pancreas disorders, Medical specialties, Health, Organ systems, Chronic pancreatitis, Pancreatitis, Exocrine pancreatic insufficiency, Cystic fibrosis, Clinical trial, Lipase, Anthera Pharmaceuticals

We are moving forward swiftly with our OPTION 2 clinical trial and are pleased to have activated the first three European clinical trials sites in Poland, said Dr. James Pennington, Chief Medical Officer of AzurRx.

Key Points: 
  • We are moving forward swiftly with our OPTION 2 clinical trial and are pleased to have activated the first three European clinical trials sites in Poland, said Dr. James Pennington, Chief Medical Officer of AzurRx.
  • James Sapirstein, Chief Executive Officer of AzurRx, added, Our team is successfully advancing both of our MS1819 clinical programs and actively initiating new clinical trial sites and screening and enrolling patients.
  • We look forward to the successful completion of the OPTION 2 monotherapy trial and the Combination therapy trial in 2021.
  • MS1819 is a recombinant lipase enzyme for the treatment of exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis.